Herve Ghesquieres, Fanny Cherblanc, Aurelien Belot, Sophie Micon, Krimo Bouabdallah, Cyril Esnault, Luc-Matthieu Fornecker, Katia Thokagevistk, Maxime Bonjour, Fontanet Bijou, Corinne Haioun, Nadine Morineau, Loïc Ysebaert, Gandhi Damaj, Benoit Tessoulin, Stéphanie Guidez, Franck Morschhauser, Catherine Thieblemont, Adrien Chauchet, Remy Gressin, Fabrice Jardin, Christophe Fruchart, Gaelle Labouré, Ludovic Fouillet, Pauline Lionne-Huyghe, Antoine Bonnet, Laure Lebras, Sandy Amorim, Cecile Leyronnas, Gaelle Olivier, Romain Guieze, Roch Houot, Vincent Launay, Bernard Drénou, Olivier Fitoussi, Laurence Detourmignies, Julie Abraham, Carole Soussain, Florence Lachenal, Gian Matteo Pica, Patrick Fogarty, Pascale Cony-Makhoul, Adeline Bernier, Sandra Le Guyader-Peyrou, Alain Monnereau, Frédéric Boissard, Cédric Rossi, Vincent Camus
Real-world data are essential to complement clinical trial (CT) data, but major challenges remain, like data quality. REal world dAta in LYmphoma and Survival in Adults (REALYSA) is a prospective non-interventional multicentric cohort started in 2018 (NCT03869619) including patients newly diagnosed with lymphoma in France. Herein is a proof-of-concept analysis on first-line DLBCL patients to (i) evaluate the capacity of the cohort to provide robust data through a multi-step validation process; (ii) assess the consistency of the results; (iii) conduct an exploratory transportability assessment of two recent phase 3 CT (POLARIX, SENIOR)...
October 24, 2023: Blood Advances